Format

Send to

Choose Destination
Clin Neuropharmacol. 2016 Mar-Apr;39(2):115-7. doi: 10.1097/WNF.0000000000000136.

Treating Schizophrenia With the Diuretic Bumetanide: A Case Report.

Author information

1
*Centre Expert Autisme Limousin, Limoges; and †Neurochlore c/o Inmed, INSERM U901, Marseilles, France.

Abstract

Administration of the diuretic and NKCC1 chloride cotransporter antagonist bumetanide reduces the severity of autism spectrum disorders in children, and this effect is mediated by a reduction of the elevated intracellular chloride concentrations and a reinforcement of GABAergic inhibition (Lemonnier et al Transl Psychiatry. 2012;2:e202; Tyzio et al Science. 2014;343:675-679). Here, we report that this treatment also reduces the severity of symptoms in an adolescent with schizophrenia. Long-term treatment reduced hallucinations significantly, suggesting that this treatment may also be useful to treat schizophrenia. Further clinical trials and experimental studies are warranted to test this hypothesis.

PMID:
26966887
DOI:
10.1097/WNF.0000000000000136
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center